Post-doctoral Scientist in Cancer Signalling Networks with Claus Jorgensen, Systems Oncology Group

Reference Number: MI/13/50
Starting Salary: range £28,500 – £38,000 (depending on qualifications and experience)
Closing Date: 13 December 2013

• Cancer Research UK Funded post in Pancreatic Cancer

• 3 year fixed term contract

The Cancer Research UK Manchester Institute ( in Manchester (UK) is a centre for excellence in cancer research.  We occupy state-of-the-art laboratories and provide exceptional core facilities, including next generation sequencing, mass-spectrometry, advanced imaging, bioinformatics, histology, and flow cytometry.  We are core-funded by Cancer Research UK (, the world’s largest cancer organisation, are an Institute of The University of Manchester (, and are juxtaposed to The Christie NHS Foundation Trust (, one of the largest cancer treatment centres in Europe.  These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes in a vibrant and dynamic city surrounded by beautiful countryside and with excellent national and international transport links. 

Dr Claus Jorgensen, Group Leader of the Systems Oncology group, is offering a Cancer research UK funded Postdoctoral Scientist position in cancer signalling networks.  The goal of the Systems Oncology group is to understand how aberrations in cellular signalling affect tumorigenesis. In particular, we are interested in understanding how signalling between cancer cells and cells in the tumour microenvironment promote tumour progression, metastasis and lead to drug resistance. Using global approaches such as proteomics, RNA interference screening and RNA sequencing we aim to identify and understand the mechanisms of cell-cell communication (Jorgensen et al Science 2009, Jorgensen et al Curr Opin Genet Dev 2010). The successful candidates will join a multidisciplinary team to study these problems.

A post is available to a candidate wishing to undertake and develop a project to analyse tumour signalling and drug resistance. The candidate will utilise next generation sequencing, proteomics, advanced microscopy and in vivo approaches. This work will support personalised/precision medicine for pancreatic cancer patients. 

The successful candidate will hold a PhD in a relevant fields and experience in proteomics and pancreatic cancer biology will be an advantage. The successful candidates will be expected to maximize publication output.   Informal enquiries can be directed to Dr Claus Jorgensen (

To apply for this position please complete an equal opportunities form and submit along with a CV and accompanying CV cover sheet detailing the names of three referees to  quoting the job reference number above. For applicants who are unable to download this information from our website, please contact HR department on 0161 446 3231, email: to have this information sent by post.

The deadline for receipt of applications is 13th December 2013 and first round interviews will take place during early January 2014.

CV cover sheet

Further Particulars

Disability Two Ticks Scheme

The University of Manchester uses the Disability Two Ticks Symbol, which is awarded by Jobcentre Plus. This symbol recognises those employers who have agreed to meet five commitments regarding the recruitment, employment, retention and career development of disabled people. More about the Disability Two Ticks Scheme

Submitting Applications

Please submit any applications using Microsoft Word (.doc) or Adobe PDF (.pdf).